Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Jung Melita Sun | Chief Business Officer | Nov 30 '24 | Buy | 5.11 | 2,250 | 11,498 | 2,250 | Feb 03 07:28 PM | | Burroughs Amy L. | Chief Executive Officer | Nov 30 '24 | Buy | 5.11 | 510 | 2,606 | 19,609 | Feb 03 07:25 PM | | Kuriakose Emil | Chief Medical Officer | Jan 02 '25 | Sale | 5.71 | 4,481 | 25,607 | 54,269 | Jan 06 07:30 PM | | Vignola Mark J. | Chief Financial Officer | Jan 06 '25 | Sale | 5.80 | 9,059 | 52,500 | 74,752 | Jan 06 07:30 PM | | Vignola Mark J. | Chief Financial Officer | Jan 02 '25 | Sale | 5.72 | 8,129 | 46,524 | 83,811 | Jan 06 07:30 PM | | Quigley Jill M. | Director | Jan 06 '25 | Sale | 5.79 | 8,760 | 50,758 | 0 | Jan 06 07:30 PM | | Quigley Jill M. | Director | Jan 02 '25 | Sale | 5.72 | 6,240 | 35,702 | 8,760 | Jan 06 07:30 PM | | MARK J VIGNOLA | Officer | Jan 06 '25 | Proposed Sale | 5.75 | 9,059 | 52,089 | | Jan 06 04:29 PM | | JILL QUIGLEY | Director | Jan 06 '25 | Proposed Sale | 5.75 | 8,760 | 50,370 | | Jan 06 04:29 PM | | Burroughs Amy L. | Chief Executive Officer | Dec 05 '24 | Buy | 7.15 | 15,450 | 110,468 | 19,099 | Dec 09 06:04 PM | | Lu Hongbo | Director | Sep 12 '24 | Buy | 10.50 | 476,190 | 4,999,995 | 476,190 | Sep 17 07:48 PM | | Vignola Mark J. | Chief Financial Officer | Sep 10 '24 | Option Exercise | 5.36 | 10,000 | 53,600 | 101,940 | Sep 12 06:10 PM | | Vignola Mark J. | Chief Financial Officer | Sep 10 '24 | Sale | 11.00 | 10,000 | 110,000 | 91,940 | Sep 12 06:10 PM | | Quigley Jill M. | Director | Sep 09 '24 | Option Exercise | 1.82 | 17,235 | 31,368 | 32,235 | Sep 11 06:00 PM | | Quigley Jill M. | Director | Sep 09 '24 | Sale | 10.00 | 17,235 | 172,350 | 15,000 | Sep 11 06:00 PM | | SEOKHO BRYAN YOON | Officer | Sep 10 '24 | Proposed Sale | 9.12 | 10,000 | 91,200 | | Sep 10 04:21 PM | | MARK J VIGNOLA | Officer | Sep 10 '24 | Proposed Sale | 9.12 | 10,000 | 91,200 | | Sep 10 04:21 PM | | JILL QUIGLEY | Officer | Sep 09 '24 | Proposed Sale | 7.81 | 8,857 | 69,173 | | Sep 09 04:30 PM | | Quigley Jill M. | Director | Aug 02 '24 | Sale | 7.50 | 8,857 | 66,432 | 15,000 | Aug 05 08:11 PM | | Quigley Jill M. | Director | Aug 01 '24 | Sale | 7.68 | 6,143 | 47,148 | 23,857 | Aug 05 08:11 PM | | GORDON CARL L | Director | Jul 15 '24 | Sale | 10.00 | 50,976 | 509,760 | 756,258 | Jul 17 08:53 PM | | GORDON CARL L | Director | Jul 16 '24 | Sale | 10.00 | 5,188 | 51,880 | 755,635 | Jul 17 08:53 PM | | ORBIMED ADVISORS LLC | Director | Jul 15 '24 | Sale | 10.00 | 50,976 | 509,760 | 756,258 | Jul 17 08:48 PM | | ORBIMED ADVISORS LLC | Director | Jul 16 '24 | Sale | 10.00 | 5,188 | 51,880 | 755,635 | Jul 17 08:48 PM | | Quigley Jill M. | Director | Jul 15 '24 | Option Exercise | 1.82 | 14,365 | 26,144 | 44,365 | Jul 17 07:56 PM | | Quigley Jill M. | Director | Jul 16 '24 | Option Exercise | 1.82 | 400 | 728 | 30,400 | Jul 17 07:56 PM | | Quigley Jill M. | Director | Jul 15 '24 | Sale | 10.00 | 14,365 | 143,660 | 30,000 | Jul 17 07:56 PM | | Quigley Jill M. | Director | Jul 16 '24 | Sale | 10.00 | 400 | 4,000 | 30,000 | Jul 17 07:56 PM | | Vivo Opportunity, LLC | 10% Owner | Apr 01 '24 | Sale | 6.99 | 181,117 | 1,266,008 | 275,772 | Apr 03 08:47 PM | | Vivo Opportunity, LLC | 10% Owner | Apr 03 '24 | Sale | 6.20 | 138,066 | 856,009 | 268,573 | Apr 03 08:47 PM | | Vivo Opportunity, LLC | 10% Owner | Apr 02 '24 | Sale | 6.65 | 101,480 | 674,842 | 272,722 | Apr 03 08:47 PM |
|
